Mirum Pharmaceuticals (FRA:08D) COGS-to-Revenue : 0.26 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Mirum Pharmaceuticals COGS-to-Revenue?

Mirum Pharmaceuticals's Cost of Goods Sold for the three months ended in Mar. 2024 was €16.4 Mil. Its Revenue for the three months ended in Mar. 2024 was €63.7 Mil.

Mirum Pharmaceuticals's COGS to Revenue for the three months ended in Mar. 2024 was 0.26.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Mirum Pharmaceuticals's Gross Margin % for the three months ended in Mar. 2024 was 74.24%.

Mirum Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Mirum Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mirum Pharmaceuticals COGS-to-Revenue Chart

Mirum Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.10

0.16

0.25

Mirum Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.16	0.18	0.21	0.36	0.26

Mirum Pharmaceuticals COGS-to-Revenue Calculation

Mirum Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	43.135	/	170.905
	=	0.25

Mirum Pharmaceuticals's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	16.403	/	63.684
	=	0.26

Mirum Pharmaceuticals (FRA:08D) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Mirum Pharmaceuticals's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	16.403 / 63.684
	=	74.24 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Mirum Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Mirum Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Mirum Pharmaceuticals (FRA:08D) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirum Pharmaceuticals Inc (FRA:08D) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

MIRM:USA MIRM:Mexico

Address

950 Tower Lane, Suite 1050, Foster City, CA, USA, 94404

Website

https://www.mirumpharma.com

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Mirum Pharmaceuticals (FRA:08D) Headlines

No Headlines